Membrane-bound ICAM-1 is upregulated by trypsin and contributes to leukocyte migration in acute pancreatitis

Werner Hartwig,1 Jens Werner,1 Andrew L. Warshaw,3 Bozena Antoniu,3 Carlos Fernandez-del Castillo,3 Martha-Maria Gebhard,2 Waldemar Uhl,1 and Markus W. Büchler1

1Departments of General and 2Experimental Surgery, University of Heidelberg, 69120 Heidelberg, Germany; and 3Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Submitted 14 May 2004 ; accepted in final form 2 August 2004


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 DISCLOSURES
 REFERENCES
 
In acute pancreatitis, ICAM-1 is upregulated in various organs and contributes to the development of organ injury. To investigate the effects of pancreatic proteases on ICAM-1 expression and their role in the early process of leukocyte migration, human umbilical vein endothelial cells (HUVECs) were incubated with serum subjected to limited trypsin digestion and Wistar rats were injected with trypsin. Significant upregulation of membrane-bound ICAM-1 was seen on HUVECs incubated with trypsinated serum. Likewise, soluble ICAM-1 increased in the supernatant of HUVECs. Changes of membrane-bound ICAM-1 and soluble ICAM-1 were maximal with high concentrations of trypsin. HUVECs incubated with TNF-{alpha} (positive control) showed similar changes. In the pancreas and lungs of animals infused with trypsin, ICAM-1 and leukocyte sequestration were increased compared with controls. Reflecting the relevance of protease-induced ICAM-1 expression in leukocyte migration, leukocyte-endothelium interaction, as assessed by intravital microscopy, was markedly increased by trypsin. Inhibition of ICAM-1 ameliorated these changes significantly. In conclusion, trypsinated serum induces the upregulation of both membrane-bound ICAM-1 on endothelial cells and soluble ICAM-1. These changes contribute to the early steps of leukocyte migration in acute pancreatitis. The role of soluble ICAM-1 remains to be investigated.

adhesion molecules; endothelial cells; proteases; systemic inflammatory response syndrome


SYSTEMIC INFLAMMATORY response syndrome (SIRS) with concomitant manifestation of multiple organ failure is frequently found in severe acute pancreatitis. A substantial number of patients develop SIRS within the first week after onset of symptoms and need intensive care treatment due to the development of cardiovascular, pulmonary, or renal insufficiency (3, 14, 21, 22). A critical role in the pathogenesis of local and distant organ injury in this setting is attributed to neutrophils. Neutrophils are activated by proinflammatory mediators and infiltrate the pancreas as well as distant organs (11, 19). The trafficking of neutrophils into tissue involves sequential leukocyte-endothelial cell interactions that are described as leukocyte rolling (low-affinity adhesion), leukocyte sticking (firm adhesion), and leukocyte transmigration. Leukocyte trafficking is mediated by complex interactions between adhesion molecules expressed on leukocytes and their corresponding ligands on endothelial cells (4, 36).

ICAM-1 (CD54), a member of the immunoglobulin superfamily, is expressed constitutively at a low extent on the surface of endothelial cells. On cell activation, ICAM-1 is upregulated and participates in the firm adhesion of leukocytes to endothelium and in transendothelial cell migration (39). In acute pancreatitis, ICAM-1 is known to be upregulated in the pancreas and lungs, and both onset and extent of ICAM-1 expression correlate with the severity of organ injury (9, 26, 41). Furthermore, genetically induced ICAM-1 deficiency or administration of monoclonal antibodies against ICAM-1 has been proven to be effective in the prevention and treatment of these complications (9, 25, 41).

Although various mediators have been implicated in the upregulation of ICAM-1 in inflammatory disease (7, 17, 30), it is yet unknown which factors are involved in this process in acute pancreatitis. Transcriptional activation of the adhesion molecules ICAM-1 and VCAM-1 expression was found when endothelial cells were incubated with ascites collected from animals with necrotizing pancreatitis (27). Recently, our laboratory (12) has demonstrated that Mac-1 (CD11b/CD18), the ligand to ICAM-1, is upregulated on neutrophils incubated with trypsinated serum, giving evidence that the serine protease trypsin induces changes in serum, which cause leukocyte activation in acute pancreatitis, possibly by complement activation. In the present study, we provide direct evidence for the central role of trypsin in the initiation of leukocyte migration and organ injury. Trypsin induces changes in serum that result in ICAM-1 expression on endothelial cells in vitro, upregulates ICAM-1 expression in the pancreas and lungs in vivo, and increases ICAM-1-dependent interaction between leukocytes and the endothelial lining.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 DISCLOSURES
 REFERENCES
 
In Vitro Experiments

Human umbilical vein endothelial cell incubations. Human umbilical vein endothelial cells (HUVECs) were plated at a concentration of 3 x 105 cells/well in 96-well, flat-bottom, microwell plates (Nunclon; Fisher Scientific, Pittsburgh, PA) and grown to confluence at 37°C in a humidified incubator with 5% CO2-95% air. For incubations, 20 µl (or 50 µl) of serum subjected to limited trypsin digestion (see Limited trypsin digestion of serum) were added to HUVECs. HUVECs incubated with TNF-{alpha} (400 and 1,000 U/l; Sigma, St. Louis, MO) or serum alone served as controls. Incubation was allowed to proceed for 3, 6, 9, 12, and 24 h at 37°C. After incubation, the supernatant was withdrawn from endothelium layers and transferred to separate Nunclon microwell plates for measurement of soluble ICAM-1. Membrane-bound as well as soluble ICAM-1 were measured quantitatively by ELISA.

Cells and cell culture. HUVECs, EBM-2 endothelial growth cell medium, and EGM-2 supplement were purchased from Clonetics (San Diego, CA). HUVECs were grown on 100 x 20-mm tissue culture-treated dishes (Corning, Corning, NY) until 70–90% confluence and then subcultured onto flat-bottom microwell plates. The plates were further incubated in the humidified incubator for 1–3 days to allow cell adherence and growth to desired density. Cells between passages 5 and 12 were used for all experiments.

Limited trypsin digestion of serum. Non-heat-inactivated bovine serum was subjected to limited trypsin digestion by incubation with bovine trypsin (final concentration 10–6–10–4 M, n = 5 samples per group) and simultaneous addition of soybean trypsin inhibitor twice the concentration of trypsin (both from Sigma). Incubations were performed for 20 min at room temperature. Unlike incubation of serum with trypsin alone, limited trypsin digestion has previously been shown to effectively activate complement components in human serum and to induce neutrophil activation (33). Significant residual trypsin activity is not present in these serum preparations as measured spectrophotometrically using p-toluenesulfonyl-L-arginine methyl ester (Sigma, St. Louis, MO) as substrate (12). After completion of incubation, trypsinated serum was frozen and stored at –80°C until being used for HUVEC incubations.

Cellular ELISA for ICAM-1. The expression of ICAM-1 on HUVECs incubated with serum subjected to limited trypsin digestion was quantified by using a modified ELISA assay as described previously (24). Briefly, after completion of the incubation protocol and subtraction of the supernatant, cells were washed with PBS/Tween buffer (PBST), fixed with 1% paraformaldehyde (Sigma) for 30 min, and washed again with PBST. Nonfat dry milk (5%) was added to reduce nonspecific binding. Cells were incubated with 100 µl of monoclonal anti-human ICAM-1 (CD54; Pharmingen, San Diego, CA), diluted 1:1,000 in culture medium for 45 min, washed 5 times with PBST, and incubated in the dark with 100 µl of biotinylated anti-mouse secondary antibody (Vector Laboratories, Burlingame, CA) for 30 min. Subsequently, cells were washed as above and incubated in the dark with 100 µl streptavidin horseradish peroxidase (DAKO, Carpinteria, CA) for 30 min. After another washing with PBST, 100 µl of TMB peroxidase substrate (tetramethyl benzidine dihydrochloride K-Blued MAX; Neogen Lexington, KY) was added for 15–30 min. The reaction was halted by the addition of 1 M sulfuric acid (50 µl/well). All incubations were carried out at room temperature. The expression of ICAM-1 was determined by the difference in absorbance at wavelength 450 vs. 630 nm measured by an automated microplate reader.

An ELISA-based cell count was performed to correct for possible differences in the amount of HUVECs in the wells after incubation with trypsinated serum or TNF-{alpha}. After the cellular ELISA for ICAM-1, cells were washed in tap water. Crystal violet (0.08%, Sigma) was added for 5 min, followed by another thorough wash in tap water. Acetic acid (33%) was used to solubilize the nuclear stain. Optical density was read at 570 nm, representing the actual cell count per well.

Likewise, soluble ICAM-1 was determined in the supernatant of incubated HUVECs. After completion of incubations, the supernatant was transferred to separate 96-well Nunclon plates. Plates were kept overnight at 4°C to allow binding of protein to the wells. ELISA was then performed as described in Cellular ELISA for ICAM-1, starting with the addition of nonfat dry milk to reduce nonspecific antibody binding. Results of soluble ICAM-1 are expressed as the percentage of ICAM-1 in the supernatant at baseline.

In Vivo Experiments

The early effects of trypsin released into the systemic circulation in acute pancreatitis were imitated in the present study by intravenous infusion of trypsin into healthy rats. Previously, it has been shown by our laboratory (12, 15) that infusion of trypsin, as well as infusion of trypsinated serum into rats, results in pancreatic and pulmonary injury similar to that found in acute pancreatitis. Unlike in vitro incubations, which necessitate serum subjected to limited trypsin digestion (see Limited trypsin digestion of serum), the presence of serum containing plenty of antiproteases in the rat allows the use of trypsin infusion for in vivo experiments.

Experimental protocol. Bovine trypsin (Sigma) was infused intravenously into rats (n = 6) for 6 h at 60 nmol·kg–1·h–1. At this concentration, trypsin causes significant pancreatic and pulmonary injury, as assessed by the wet-to-dry ratio, myeloperoxidase activity, and histology (15). Infusions were divided into 3 aliquots/h, and each aliquot was freshly reconstituted in saline before injection to minimize autodigestion of trypsin. Saline was infused into control animals. At 6 h after the start of infusions, leukocyte-endothelium interaction and capillary blood flow were assessed in the head of the pancreas by intravital microscopy. In additional animals infused with trypsin, ICAM-1 expression in the pancreas and lungs was measured by Western blot analysis. Pancreatic and pulmonary leukocyte sequestration was assessed by activity of myeloperoxidase, an enzyme stored in the azurophilic granules of neutrophils. To evaluate whether changes in leukocyte-endothelial interaction induced by trypsin are related to ICAM-1 upregulation, one group of animals (n = 6) was pretreated with purified anti-rat ICAM-1 antibody (1.0 mg/kg; Pharmingen) before trypsin infusions were started.

Animals. Inbred male Wistar rats weighing 250–300 g were used for experiments. Care was provided in accordance with the German law for care and use of laboratory animals. The study was approved by the Regierungspräsidium Karlsruhe, Germany, committee on animal care. Animals were fasted overnight before the experiments but allowed free access to water.

Anesthesia and catheter placement. Surgical anesthesia was induced by intraperitoneal injection of pentobarbital sodium (10 mg/kg, Nembutal; Sanofi-Ceva, Genova, Germany) and intramuscular injection of ketamine (40 mg/kg Ketanest 50; Parke-Davis, Berlin, Germany). Two polyethylene catheters (ID, 0.5 mm) were inserted into the left carotid artery and the right internal jugular vein, respectively, tunneled subcutaneously to the suprascapular area, and exited through a steel tether that allowed the animals free movement. The venous catheter was used for infusion regimens, and the arterial line was used for blood sampling and hemodynamic monitoring.

Intravital microscopy. Microcirculatory changes of the pancreas caused by trypsin infusion were assessed by intravital microscopy as described in detail elsewhere (16). Briefly, after a midline laparotomy was performed, the pancreas with the duodenal loop was gently exteriorized and placed in an immersion chamber containing Ringers lactate maintained at 37°C. The pancreatic microcirculation was then evaluated in epi-illumination using a fluorescence microscope (Fa. Leitz, Wetzlar, Germany). Therefore, animals were injected with FITC-labeled erythrocytes (0.5 ml/kg, hematocrit 50%) for capillary blood flow measurements and Rhodamin 6G (bolus of 0.1 ml) for in vivo staining of leukocytes and quantitation of leukocyte-endothelium interaction. Mean capillary red blood cell velocity was analyzed in four different regions of the pancreas in each rat. The mean red blood cell velocity in each area was calculated by averaging the velocity of erythrocytes in 15 ± 2 capillaries. According to their interaction with the endothelial lining, adherent and rolling leukocytes were assessed in postcapillary venules with a diameter of 25–40 µm. Adherent leukocytes (stickers) were defined as cells that did not move or detach from the endothelium within the observation period of 30 s (10). Rolling leukocytes (rollers) were defined as those white cells moving at a velocity less than two-thirds of that of erythrocytes in the centerline of the venule (42). Both stickers and rollers were expressed as the number of cells per square millimeter of vessel surface, calculated from the diameter and length (100 µm) of the vessel segment studied. Off-line analysis of video recordings was performed in a blinded fashion using a computer-assisted microcirculation analysis system (Cap Image; Dr. H. Zeintl, Heidelberg, Germany).

Gel electrophoresis and Western blot analysis. Pancreas and lung tissue were homogenized in sodium phosphate buffer containing 0.5% hexadecyltrimethylammonium bromide (Sigma) and 5% soybean trypsin inhibitor at a tissue-to-buffer ratio of 1:1.5. Protein concentration was determined by protein assay (Pierce, Perbio Science Deutschland, Bonn, Germany) and adjusted to a final protein concentration of 1.8 mg/ml. Electrophoresis was performed by SDS-PAGE. A total of 30 µl of tissue sample per well was loaded on the gel in nonreducing sample buffer. After electrophoresis, the proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad, München, Germany). The blotted membrane was blocked with nonfat dry milk (5%) in TBS/Tween-buffer (TBST) and agitated for 2 h with a mouse anti-rat ICAM-1 antibody (1:100 dilution in TBST; Serotec, Düsseldorf, Germany). After samples were washed with TBST, the secondary reagent, goat anti-mouse IgG linked to horseradish peroxidase (1:10,000 dilution, Linaris, Wertheim-Bettingen, Germany) was added. After repeated washing with TBST, the membrane was rinsed with water. The method of enhanced chemiluminescence (ECL Plus; Amersham Biosciences, Freiburg, Germany) was chosen for detection, according to the manufacturer's instruction. All incubations were carried out at room temperature.

Myeloperoxidase activity. Excised pancreatic and pulmonary tissues were rinsed with saline, blotted dry, snap frozen in liquid nitrogen, and stored at –80°C until thawing for determination of myeloperoxidase activity as previously described (15).

Statistical Analysis

Data are presented as means ± SE. One-way ANOVA was used for evaluation of differences between groups (when >2), followed by post hoc comparison of the means of the groups. Student's t-test was used for pairwise comparison of normal, distributed parameters. Values of P < 0.05 were considered significant.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 DISCLOSURES
 REFERENCES
 
In Vitro Experiments

ICAM-1 expression on HUVECs. The expression of ICAM-1 on HUVECs incubated with trypsinated serum was significantly increased compared with controls incubated with untreated serum. Levels of ICAM-1 expression increased with higher concentrations of trypsin used for serum trypsination (Fig. 1). Highest levels of ICAM-1 expression were found at 9 h after the start of incubations. Larger amounts of trypsinated serum used for serum incubations (50 instead of 20 µl) did not further increase ICAM-1 expression. However, peak levels of ICAM-1 occurred earlier (data not shown).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1. Membrane-bound ICAM-1 on human umbilical vein endothelial cells (HUVECs). The expression of membrane-bound ICAM-1 on HUVECs was measured by a cellular ELISA. HUVECs were incubated with serum subjected to limited trypsin digestion, untreated serum (control), or with TNF-{alpha}. The expression of ICAM-1 was determined by the differences in absorbance at wavelength 450 vs. 630 nm. OD, optical density.

 
HUVECs incubated with TNF-{alpha} showed similar changes and served as positive controls (Fig. 1). No significant changes of ICAM-1 expression were found when HUVECs were incubated with medium or untreated serum (Fig. 1). The ELISA-based cell count, which was performed to correct for differences in the amount of cells per well, did not show any significant differences among incubations with medium, control serum, trypsinated serum, or TNF-{alpha}.

Similar to membrane-bound ICAM-1, significant amounts of soluble ICAM-1 were found in the supernatant of HUVECs stimulated with trypsinated serum. Again, levels of soluble ICAM-1 increased with higher amounts of trypsin used for serum trypsination (Fig. 2). When trypsin was used at a concentration of 10–4 M, levels of soluble ICAM-1 peaked at 9 h of HUVEC incubation but decreased significantly thereafter. HUVECs incubated with TNF-{alpha} showed highest levels of soluble ICAM-1 at 12 h. Unlike incubations with trypsinated serum, soluble ICAM-1 levels remained elevated for the entire observation period of 24 h (Fig. 2).



View larger version (15K):
[in this window]
[in a new window]
 
Fig. 2. Soluble ICAM-1 was determined in the supernatant of incubated HUVECs. Soluble ICAM-1 is expressed as the percentage of ICAM-1 in incubations with control serum.

 
In Vivo Experiments

In confirmation of our in vitro findings, Western blot analysis demonstrated higher levels of ICAM-1 expression in the lungs of animals injected with trypsin compared with control animals injected with saline only (Fig. 3). ICAM-1 expression was more pronounced in the lungs than in the pancreas. Likewise, animals showed significant organ injury with significant leukocyte sequestration in the pancreas and lungs as determined by myeloperoxidase activity (pancreas: 13.3 ± 1.9 vs. 6.1 ± 0.9 U/mg; lungs: 112.2 ± 9.7 vs. 47.8 ± 7.2 U/mg; both trypsin vs. control). This is in agreement with previous studies (15).



View larger version (41K):
[in this window]
[in a new window]
 
Fig. 3. Immunoblots of ICAM-1 in pancreas and lung tissue. The expression of ICAM-1 in the pancreas and lungs of trypsin-infused animals and control animals was assessed by Western blot analysis. The monoclonal antibody used for blotting showed cross-reactivity with recombinant human ICAM-1, which served as a control marker.

 
Both rollers and stickers were significantly increased in the pancreatic microvasculature of animals infused with trypsin compared with controls that were injected with saline only (both P < 0.001 vs. control, Fig. 4). At the same time, pancreatic microcirculatory perfusion decreased significantly in these animals (P < 0.01, Fig. 5). Importantly, macrohemodynamic parameters did not show any significant changes among the groups (data not shown).



View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4. Rolling (A) and adherent (B) leukocytes were assessed in postcapillary venules of the pancreas with a diameter of 25–40 µm. Adherent leukocytes (stickers) were defined as cells that did not move or detach from the endothelium within the observation period of 30 s. Rolling leukocytes (rollers) were defined as those white cells moving at a velocity of that of erythrocytes in the centerline of the venule. Both stickers and rollers were expressed as the number of cells per square millimeter of vessel surface. *P < 0.01 vs. control, {dagger}P = 0.04 vs. trypsin only.

 


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5. As a determinant of microcirculatory perfusion of the pancreas, mean capillary red blood cell (RBC) velocity was analyzed in four different regions of the pancreas in each rat. The mean blood cell velocity in each area was calculated by averaging the velocity of erythrocytes in 15 ± 2 capillaries. Results are expressed as mm/s. *P < 0.001 vs. control, {dagger}P = 0.03 vs. trypsin only.

 
When animals infused with trypsin were pretreated with a monoclonal antibody against ICAM-1, the number of stickers was significantly decreased compared with animals without pretreatment (P = 0.04, Fig. 4B). Likewise, pancreatic perfusion was less profoundly reduced with anti-ICAM-1 pretreatment (P = 0.03, Fig. 5). However, no significant differences were found in rolling leukocytes (Fig. 4A).


    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 DISCLOSURES
 REFERENCES
 
Systemic complications are frequently associated with SIRS in the early phase of acute pancreatitis, and neutrophils play a critical role in the pathogenesis of these complications. ICAM-1, an adhesion molecule of the immunoglobulin superfamily, contributes to the firm adhesion of leukocytes to the endothelium and their subsequent transendothelial migration (39). It is constitutively expressed on endothelial and epithelial cells and to a lesser extent on leukocytes. However, ICAM-1 expression is induced in a cell-specific manner by several proinflammatory mediators (7, 17, 30). In the present study, we have demonstrated that ICAM-1 is upregulated on endothelial cells that were stimulated by trypsinated serum. ICAM-1 expression was maximal when high trypsin concentrations were used for serum incubations and peaked at 6–9 h of HUVEC stimulation. This time interval is possibly explained by the transcriptional regulation of ICAM-1. Interestingly, expression levels of ICAM-1 induced by trypsinated serum were similar to those found with TNF-{alpha} incubation, reflecting the high potential of trypsinated serum to activate endothelial cells.

In agreement with these in vitro findings, we demonstrated that ICAM-1 expression is also increased by trypsin in vivo. This increase of ICAM-1 expression was more pronounced in the lungs compared with the pancreas, possibly because of the extended pulmonary microvasculature. Associated with the increased ICAM-1 expression in trypsin-infused animals was the development of organ injury, markedly of the lungs. Similar to pancreatitis-associated lung injury, this injury is of a neutrophil-dependent character (15). Applying intravital microscopy, a method that allows the investigation of leukocyte-endothelium interaction and microvascular perfusion of organs in real-time conditions in vivo, we have found convincing evidence that the observed trypsin-induced changes in adhesion molecule expression are relevant for the process of leukocyte migration. In the pancreas of animals infused with trypsin, the amounts of rollers and stickers were markedly increased compared with controls. Infusion of an antibody against ICAM-1 resulted in the amelioration of these changes. These findings support the hypothesis that the upregulation of ICAM-1 by proteases released from the pancreas may also be relevant in the pathogenesis of pancreatitis-associated organ injury.

In acute pancreatitis, ICAM-1 is upregulated in both the pancreas and the lungs, and the extent of ICAM-1 expression correlates with the severity of organ injury (26, 41). In previous studies (11, 15, 40), we have shown that the occurrence and severity of pancreatitis-associated lung injury corresponds to the levels of circulating trypsinogen and its activation to trypsin and that neutrophils are involved in the development of this injury. Furthermore, it has been demonstrated that the expression of Mac-1 (CD11b/CD18), the ligand to endothelial ICAM-1, is increased on the surface of neutrophils incubated with trypsinated serum (12). Mac-1, a membrane-bound adhesion molecule of the integrin group, is primarily expressed on the surface of neutrophils on stimulation. There is general agreement that the firm adhesion of neutrophils to the endothelial lining is, at least in part, mediated by the interaction of ICAM-1 and Mac-1 (4). With the indirect trypsin-induced upregulation of both Mac-1 and ICAM-1, we have identified trypsin as a mediator capable of inducing neutrophil and endothelium activation, followed by extravasation of cells and manifestation of organ injury in acute pancreatitis.

Serine protease trypsin has been assumed for a long time to cause local and distant organ injury in acute pancreatitis. Whereas intra-acinar and interstitial trypsinogen activation are widely accepted to be central events in the early pathogenesis of acute pancreatitis (8, 13, 37), the role of trypsin in the pathogenesis of distant organ injury is controversial. Although selective trypsin infusion caused lung injury in several animal models (5, 15, 38), systemic trypsin has been questioned as playing a significant role in acute pancreatitis due to its quick binding to protease inhibitors. In the present study, we demonstrate that trypsin-induced changes in serum can induce adhesion molecule expression and thereby initiate leukocyte migration into tissue. The limited trypsin digestion of serum, as applied in our study, included the simultaneous addition of soybean trypsin inhibitor twice the concentration of trypsin. Unlike trypsin alone, using this procedure has also been demonstrated as inducing neutrophil activation with subsequent induction of the respiratory burst (33). It may closely reflect in vivo conditions in which protease inhibitors are present in excess.

Recently, several studies (1, 27) have focused on the regulation of adhesion molecules in acute pancreatitis. Confirming our results, increased expression of Mac-1 or ICAM-1 was found on neutrophils and endothelial cells incubated with serum or ascites from animals with acute pancreatitis. The proinflammatory substances that are possibly inducing this cell activation include proteases other than trypsin, cytokines, or complement proteins. Interestingly, complement activation has been demonstrated by trypsin (2, 28, 33) and also in acute pancreatitis (18, 34). Therefore, complement proteins may mediate the trypsin-induced leukocyte activation and thereby contribute to the development of systemic organ injury in acute pancreatitis (12).

Most of the membrane-bound adhesion molecules are also known to exist in a soluble form. Soluble ICAM-1 was first described in 1991 (32, 35) in the blood of healthy human subjects. Subsequently, a number of studies (6, 20, 29) reported increased levels of soluble ICAM-1 in inflammatory disease, but little is known about soluble ICAM-1 in acute pancreatitis. Our in vitro experiments showed elevated levels of soluble ICAM-1 in the supernatant of HUVECs activated by trypsinated serum, and soluble ICAM-1 increased with higher amounts of trypsin used for serum trypsination. This finding is in agreement with the proposal that soluble adhesion molecules may reflect endothelial cell activation and the magnitude of expression of their membrane-bound counterparts. Whether the circulating levels of soluble ICAM-1 are useful markers or predictors for the severity of acute pancreatitis, as suggested by recent studies (23, 31), remains to be investigated.

In summary, we have demonstrated that trypsin induces changes in serum that result in upregulation of ICAM-1 and in leukocyte migration. Inhibition of ICAM-1 expression may be a potential therapy of systemic complications in acute pancreatitis. A diagnostic tool may be available by measurement of soluble ICAM-1 in serum of patients.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 DISCLOSURES
 REFERENCES
 
Deutsche Akademie der Naturforscher Leopoldina Grant BMBF-LPD 9801–14 (to W. Hartwig).


    DISCLOSURES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 DISCLOSURES
 REFERENCES
 
Data from this study were presented at the American Pancreatic Association (Chicago, IL, November 1–3, 2001) and at the combined meeting of the International Association of Pancreatology and the European Pancreas Club (Heidelberg, Germany, June 19–22, 2002).


    FOOTNOTES
 

Address for reprint requests and other correspondence: M. W. Büchler, Dept. of General Surgery, Univ. of Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany (E-mail: markus_buechler{at}med.uni-heidelberg.de)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 DISCLOSURES
 REFERENCES
 

  1. Acioli JM, Isobe M, and Kawasaki S. Early complement system activation and neutrophil priming in acute pancreatitis: participation of trypsin. Surgery 122: 909–917, 1997.[ISI][Medline]
  2. Bokisch VA, Dierich MP, and Muller-Eberhard HJ. Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci USA 72: 1989–1993, 1975.[Abstract]
  3. Büchler MW, Gloor B, Müller CA, Friess H, Seiler CA, and Uhl W. Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg 232: 619–626, 2000.[CrossRef][ISI][Medline]
  4. Carlos TM and Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 84: 2068–2101, 1994.[Abstract/Free Full Text]
  5. Cohler LF, Saba TM, and Lewis EP. Lung vascular injury with protease infusion. Relationship to plasma fibronectin. Ann Surg 202: 240–247, 1985.[ISI][Medline]
  6. Cowley HC, Heney D, Gearing AJ, Hemingway I, and Webster NR. Increased circulating adhesion molecule concentrations in patients with the systemic inflammatory response syndrome: a prospective cohort study. Crit Care Med 22: 651–657, 1994.[ISI][Medline]
  7. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, and Springer TA. Induction by IL-1 and interferon-{gamma}: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 137: 245–254, 1986.[Abstract/Free Full Text]
  8. Fernandez-del Castillo C, Schmidt J, Warshaw AL, and Rattner DW. Interstitial protease activation is the central event in progression to necrotizing pancreatitis. Surgery 116: 497–504, 1994.[ISI][Medline]
  9. Frossard JL, Saluja A, Bhagat L, Lee HS, Bhatia M, Hofbauer B, and Steer ML. The role of intercellular adhesion molecule 1 and neutrophils in acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology 116: 694–701, 1999.[ISI][Medline]
  10. Gaboury JP and Kubes P. Reductions in physiologic shear rates lead to CD11/CD18-dependent, selectin-independent leukocyte rolling in vivo. Blood 83: 345–350, 1994.[Abstract/Free Full Text]
  11. Hartwig W, Carter EA, Jimenez RE, Jones R, Fischman AJ, Fernandez-del Castillo C, and Warshaw AL. Neutrophil metabolic activity but not neutrophil sequestration reflects the development of pancreatitis-associated lung injury. Crit Care Med 30: 2075–2082, 2002.[CrossRef][ISI][Medline]
  12. Hartwig W, Jimenez RE, Fernandez-del Castillo C, Kelliher A, Jones R, and Warshaw AL. Expression of the adhesion molecules Mac-1 and L-selectin on neutrophils in acute pancreatitis is protease- and complement-dependent. Ann Surg 233: 371–378, 2001.[CrossRef][ISI][Medline]
  13. Hartwig W, Jimenez RE, Werner J, Lewandrowski K, Warshaw AL, and Fernandez-del Castillo C. Interstitial trypsinogen release and its relevance to the transformation of mild into necrotizing pancreatitis in rats. Gastroenterology 117: 717–725, 1999.[ISI][Medline]
  14. Hartwig W, Maksan SM, Foitzik T, Schmidt J, Herfarth C, and Klar E. Reduction in mortality with delayed surgical therapy of severe pancreatitis. J Gastrointest Surg 6: 481–487, 2002.[CrossRef][ISI][Medline]
  15. Hartwig W, Werner J, Jimenez RE, Z'graggen K, Weimann J, Lewandrowski KB, Warshaw AL, and Fernandez-del Castillo C. Trypsin and activation of circulating trypsinogen contribute to pancreatitis-associated lung injury. Am J Physiol Gastrointest Liver Physiol 277: G1008–G1016, 1999.[Abstract/Free Full Text]
  16. Hartwig W, Werner J, Ryschich E, Mayer H, Schmidt J, Gebhard MM, Herfarth C, and Klar E. Cigarette smoke enhances ethanol-induced pancreatic injury. Pancreas 21: 272–278, 2000.[ISI][Medline]
  17. Henninger DD, Panes J, Eppihimer M, Russell J, Gerritsen M, Anderson DC, and Granger DN. Cytokine-induced VCAM-1 and ICAM-1 expression in different organs of the mouse. J Immunol 158: 1825–1832, 1997.[Abstract]
  18. Horn JK, Ranson JH, Goldstein IM, Weissler J, Curatola D, Taylor R, and Perez HD. Evidence of complement catabolism in experimental acute pancreatitis. Am J Pathol 101: 205–216, 1980.[Abstract]
  19. Inoue S, Nakao A, Kishimoto W, Murakami H, Itoh K, Itoh T, Harada A, Nonami T, and Takagi H. Anti-neutrophil antibody attenuates the severity of acute lung injury in rats with experimental acute pancreatitis. Arch Surg 130: 93–98, 1995.[Abstract]
  20. Jakobsen PH, Morris-Jones S, Ronn A, Hviid L, Theander TG, Elhassan IM, Bygbjerg IC, and Greenwood BM. Increased plasma concentrations of sICAM-1, sVCAM-1 and sELAM-1 in patients with Plasmodium falciparum or P. vivax malaria and association with disease severity. Immunology 83: 665–669, 1994.[ISI][Medline]
  21. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SK, Skaife P, Leeder PC, Wilson P, Larvin M, and Curtis LD. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 48: 62–69, 2001.[Abstract/Free Full Text]
  22. Karimgani I, Porter KA, Langevin RE, and Banks PA. Prognostic factors in sterile pancreatic necrosis. Gastroenterology 103: 1636–1640, 1992.[ISI][Medline]
  23. Kaufmann P, Smolle KH, Brunner GA, Demel U, Tilz GP, and Krejs GJ. Relation of serial measurements of plasma-soluble intercellular adhesion molecule-1 to severity of acute pancreatitis. Am J Gastroenterol 94: 2412–2416, 1999.[CrossRef][ISI][Medline]
  24. Kvale D, Krajci P, and Brandtzaeg P. Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines. Scand J Immunol 35: 669–676, 1992.[ISI][Medline]
  25. Lundberg AH, Fukatsu K, Gaber L, Callicutt S, Kotb M, Wilcox H, Kudsk K, and Gaber AO. Blocking pulmonary ICAM-1 expression ameliorates lung injury in established diet-induced pancreatitis. Ann Surg 233: 213–220, 2001.[CrossRef][ISI][Medline]
  26. Lundberg AH, Granger N, Russell J, Callicutt S, Gaber LW, Kotb M, Sabek O, and Gaber AO. Temporal correlation of tumor necrosis factor-{alpha} release, upregulation of pulmonary ICAM-1 and VCAM-1, neutrophil sequestration, and lung injury in diet-induced pancreatitis. J Gastrointest Surg 4: 248–257, 2000.[CrossRef][ISI][Medline]
  27. Masamune A, Shimosegawa T, Kimura K, Fujita M, Sato A, Koizumi M, and Toyota T. Specific induction of adhesion molecules in human vascular endothelial cells by rat experimental pancreatitis-associated ascitic fluids. Pancreas 18: 141–150, 1999.[ISI][Medline]
  28. Minta JO and Man DP. Cleavage of human C5 by trypsin: characterization of the digestion products by gel electrophoresis. J Immunol 119: 1597–1602, 1977.[Abstract]
  29. Moss M, Gillespie MK, Ackerson L, Moore FA, Moore EE, and Parsons PE. Endothelial cell activity varies in patients at risk for the adult respiratory distress syndrome. Crit Care Med 24: 1782–1786, 1996.[ISI][Medline]
  30. Mulligan MS, Vaporciyan AA, Miyasaka M, Tamatani T, and Ward PA. Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol 142: 1739–1749, 1993.[Abstract]
  31. Nakae H, Endo S, Sato N, Wakabayashi G, Inada K, and Sato S. Involvement of soluble adhesion molecules in acute pancreatitis. Eur Surg Res 33: 377–382, 2001.[CrossRef][ISI][Medline]
  32. Rothlein R, Mainolfi EA, Czajkowski M, and Marlin SD. A form of circulating ICAM-1 in human serum. J Immunol 147: 3788–3793, 1991.[Abstract/Free Full Text]
  33. Roxvall L, Bengtson A, Sennerby L, and Heideman M. Activation of the complement cascade by trypsin. Biol Chem Hoppe Seyler 372: 273–278, 1991.[ISI][Medline]
  34. Roxvall LI, Bengtson LA, and Heideman JM. Anaphylatoxins and terminal complement complexes in pancreatitis. Evidence of complement activation in plasma and ascites fluid of patients with acute pancreatitis. Arch Surg 125: 918–921, 1990.[Abstract]
  35. Seth R, Raymond FD, and Makgoba MW. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 338: 83–84, 1991.[ISI][Medline]
  36. Springer TA. Adhesion receptors of the immune system. Nature 346: 425–434, 1990.[CrossRef][ISI][Medline]
  37. Steer ML and Saluja AK. Lysosomal enzymes and pancreatitis. Gastroenterology 110: 965–967, 1996.[ISI][Medline]
  38. Tahamont MV, Barie PS, Blumenstock FA, Hussain MH, and Malik AB. Increased lung vascular permeability after pancreatitis and trypsin infusion. Am J Pathol 109: 15–26, 1982.[Abstract]
  39. Van de Stolpe A and van der Saag PT. Intercellular adhesion molecule-1. J Mol Med 74: 13–33, 1996.[ISI][Medline]
  40. Werner J, Dragotakes SC, Fernandez-del Castillo C, Rivera JA, Ou J, Rattner DW, Fischman AJ, and Warshaw AL. Technetium-99m-labeled white blood cells: a new method to define the local and systemic role of leukocytes in acute experimental pancreatitis. Ann Surg 227: 86–94, 1998.[CrossRef][ISI][Medline]
  41. Werner J, Z'graggen K, Fernandez-del Castillo C, Lewandrowski KB, Compton CC, and Warshaw AL. Specific therapy for local and systemic complications of acute pancreatitis with monoclonal antibodies against ICAM-1. Ann Surg 229: 834–840, 1999.[CrossRef][ISI][Medline]
  42. Zimmerman BJ, Holt JW, Paulson JC, Anderson DC, Miyasaka M, Tamatani T, Todd RF, Rusche JR, and Granger DN. Molecular determinants of lipid mediator-induced leukocyte adherence and emigration in rat mesenteric venules. Am J Physiol Heart Circ Physiol 266: H847–H853, 1994.[Abstract/Free Full Text]




This Article
Abstract
Full Text (PDF)
All Versions of this Article:
287/6/G1194    most recent
00221.2004v1
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Google Scholar
Articles by Hartwig, W.
Articles by Büchler, M. W.
Articles citing this Article
PubMed
PubMed Citation
Articles by Hartwig, W.
Articles by Büchler, M. W.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.